Allogene Therapeutics Inc (ALLO)

Allogene Therapeutics Inc (ALLO) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $504M; returns 1 day +0.0%, 1 week -4.6%, 1 year +3.3%.

Allogene Therapeutics Inc. is a clinical-stage biotechnology company focused on pioneering the development of 'off-the-shelf' allogeneic chimeric antigen receptor T-cell (AlloCAR T™) therapies. Unlike autologous CAR T therapies that require patient-specific manufacturing, Allogene's approach uses donor-derived cells, aiming to provide more rapid, scalable, and accessible treatment options.

Groups ALLO belongs to

• Biotechnology
• Clinical Stage
• Clinical Stage Biotech
• Immunotherapy
• Healthcare
• Oncology
• Autoimmune Diseases

ALLO financial model: income statement, cash flow and balance sheet